Common HIV/AIDS Clinical Symptoms among HIV-Positive Pregnant Women under ARV Therapy: Clinical Indicators for Non- Adherence to Treatment

Download Article

DOI: 10.21522/TIJNR.2015.03.02.Art020

Authors : Admirabilis Kalolella


The objective of this study was to assess adherence to option B+ ARV triple therapy and describe common HIV/AIDS clinical symptoms as indicators of non-adherence among women giving birth in Dar es Salaam Tanzania. We analyzed the prevalence of non- adherence through clinical assessment of common HIV/AIDS symptoms, indicators of non-adherence to treatment.

The cross section method, clinical assessment and self-report interview was used to identify clinical symptoms related to HIV/AIDS. The study analyzed symptoms with higher frequency of occurrence and were termed as common HIV/AIDS clinical symptoms, and were established as indicators of non- adherence. Women with three or more of these symptoms were identified as non- adherents to ART. The study also analyzed the relationship of demographic variables and adherence.

Result. Among the 105 HIV infected women under triple therapy, 63(60%) of them developed at least three HIV/AIDS related symptoms indicating that they were not adhering to the treatment, while 42(40%) adhered to the ARV therapy prescribed. The Adherence to ART Indicators tool was established presence or absence of persistent clinical symptoms of; fatigue, night sweat, muscle ache and frequently fever, extreme and unexplained tiredness, pneumonia, recurring fever, profuse night sweats, and rapid weight loss. Demographic variables were not significant related to adherence.

In conclusion, the majority of HIV infected pregnant women receiving B+ ARV triple therapy developed common HIV/AIDS clinical symptoms, indicating they were not adhering to treatment.

Keywords: Clinical assessment, non-adherence to ART, HIV infected pregnant women, HIV/AIDS symptoms, B+ ARV triple therapy, PMTCT.


[1]. Avert (2016). HIV and AIDS in Tanzania; UNAID gap report; Global information and education on HIV and AIDS Retrieved on 15february, 2016 from.

[2]. Calvert C, Ronsmans C. (2015). Pregnancy and HIV disease progression: a systematic review and meta-analysis. Journal of Tropical Medicine and International Health, 20(2):122-45. Retrieved June 5, 2016, from PubMed.

[3]. Kilewo Charles, Katarina Karlsson, Matilda Ngarina, Augustine Massawe, Eligius Lyamuya, Andrew Swai, Rosina Lipyoga, Fred Mhalu, Gunnel Biberfeld. Prevention of Mother to Child Transmission of HIV-1 through Breastfeeding by Treating Mothers with triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus study. Journal of Acquired Immune Deficiency Syndromes. 2009, 53: 406-41.

[4]. Kowalska A, Niemiec T, El Midaoui A, Burkacka E. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women. Med Wieku Rozwoj. 2003 Oct-Dec; 7 (4 Pt 1):459-68.

[5]. Kupka, R., Kassaye, T., Saathoff, E., Hertzmark, E., Msamanga, G. I. And Fawzi, W. W. (2009). Predictors of stillbirth among HIV-infected Tanzanian women. Journal of Acta Obstetricia et Gynecologica Scandinavica, 88: 584–592. Retrieved June 5, 2016, from PubMed.

[6]. Moodley J, Wennberg JL. HIV in pregnancy. Curr Opin Obstet Gynecol. 2005 Apr; 17(2):117-21.

[7]. Ngarina Matilda, Rebecca Popenoe, Charles Kilewo, Gunnel Biberfeld, Anna Mia Ekström. Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health. 2013, 13:450.

[8]. Ngarina M, Tarimo EAM, Naburi H, Kilewo C, Mwanyika-Sando M, Chalamilla G, et al. (2014) Women's Preferences Regarding Infant or Maternal Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission of HIV during Breastfeeding and Their Views on Option B+ in Dar es Salaam, Tanzania. PLoS ONE 9(1): e85310. doi:10.1371/journal.pone.0085310.

[9]. Reitter A1, Stücker AU, Linde R, Königs C, Knecht G, Herrmann E, Schlößer R, Louwen F, Haberl A. Pregnancy complications in HIV-positive women: 11-year data from the Frankfurt HIV Cohort. HIV Med. 2014 Oct; 15 (9):525-36. doi: 10.1111/hiv.12142. Epub 2014 Mar 6.

[10].  Siegfried N1, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011 Jul 6; (7):CD003510. doi: 10.1002/14651858.CD003510.pub3.

[11].  Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007 Jun; 32(3): 293-311.

[12].  Tanzania PMTCT. National resource centre for prevention of mother to child HIV transmission (2016). Retrieved June 15 2016 from

[13].  UNAIDS .2012. Joint United Nations Programme on HIV/AIDS (Global report: UNAIDS report on the global AIDS epidemic 2012. Retrieved May 17, 2016, from


[15].  WHO (2007). Who case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Retrieved June 15 2016 from

[16].  WHO (2015) Guideline on when to start antiretroviral therapy and on pre Exposure prophylaxis for HIV (pdf). Retrieved June 15 2016 from